Key takeaways:

In a real-world cohort of patients with obesity and heart disease but not diabetes, semaglutide prevented more CV events than tirzepatide.

The cardioprotective benefit of semaglutide may be molecule-specific.

In a real-world population of patients with obesity and atherosclerotic CVD but no diabetes, semaglutide conferred a lower rate of CV events compared with tirzepatide, researchers reported at the European Society of Cardiology Congress.

Researchers from Novo Nordisk, the manufacturer of semaglutide 2.4 mg (Wegovy), conducted the STEER retrospective, real-world study comparing patients from the U.S. Komodo Research Database who initiated semaglutide 2.4 mg or tirzepatide (Zepbound, Eli Lilly) on or after May 13, 2022. All patients were aged at least 45 years, had o

See Full Page